Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issue
22-2
Table of Contents
Editors Selection
Glaucoma Dialogue
Glaucoma Opinion
Abstracts
Abstracts
Abstracted Journals
Classification List
Index of Authors
Search
Home
Abstracts
Journals
Journal #2602
advertisement
Frontiers in pharmacology
21
Showing records 1 to 21 |
Display all abstracts in
Frontiers in pharmacology
95270
Cell-Free Biological Approach for Corneal Stromal Wound Healing
Jhanji V
Frontiers in pharmacology
2021; 12: 671405
94240
ATP and Adenosine in the Retina and Retinal Diseases
Ye SS
Frontiers in pharmacology
2021; 12: 654445
95125
The Potential of Lisosan G as a Possible Treatment for Glaucoma
Amato R
Frontiers in pharmacology
2021; 12: 719951
95446
Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
Conti F
Frontiers in pharmacology
2021; 12: 705405
95270
Cell-Free Biological Approach for Corneal Stromal Wound Healing
Billig I
Frontiers in pharmacology
2021; 12: 671405
94240
ATP and Adenosine in the Retina and Retinal Diseases
Tang Y
Frontiers in pharmacology
2021; 12: 654445
95446
Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
Romano GL
Frontiers in pharmacology
2021; 12: 705405
95125
The Potential of Lisosan G as a Possible Treatment for Glaucoma
Rossino MG
Frontiers in pharmacology
2021; 12: 719951
95446
Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
Eandi CM
Frontiers in pharmacology
2021; 12: 705405
95270
Cell-Free Biological Approach for Corneal Stromal Wound Healing
Yam GH
Frontiers in pharmacology
2021; 12: 671405
94240
ATP and Adenosine in the Retina and Retinal Diseases
Song JT
Frontiers in pharmacology
2021; 12: 654445
95125
The Potential of Lisosan G as a Possible Treatment for Glaucoma
Cammalleri M
Frontiers in pharmacology
2021; 12: 719951
95446
Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
Toro MD
Frontiers in pharmacology
2021; 12: 705405
95125
The Potential of Lisosan G as a Possible Treatment for Glaucoma
Timperio AM
Frontiers in pharmacology
2021; 12: 719951
95446
Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
Rejdak R
Frontiers in pharmacology
2021; 12: 705405
95125
The Potential of Lisosan G as a Possible Treatment for Glaucoma
Fanelli G
Frontiers in pharmacology
2021; 12: 719951
95446
Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
Di Benedetto G
Frontiers in pharmacology
2021; 12: 705405
95125
The Potential of Lisosan G as a Possible Treatment for Glaucoma
Dal Monte M
Frontiers in pharmacology
2021; 12: 719951
95446
Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
Lazzara F
Frontiers in pharmacology
2021; 12: 705405
95125
The Potential of Lisosan G as a Possible Treatment for Glaucoma
Pucci L; Casini G
Frontiers in pharmacology
2021; 12: 719951
95446
Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
Bernardini R; Drago F; Cantarella G; Bucolo C
Frontiers in pharmacology
2021; 12: 705405
Issue
22-2
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
24-1 (2024)
23-4 (2023)
23-3 (2023)
23-2 (2023)
23-1 (2022)
22-4 (2022)
22-3 (2022)
22-2 (2021)
22-1 (2021)
21-4 (2021)
21-3 (2021)
21-2 (2021)
21-1 (2020)
20-4 (2020)
20-3 (2020)
20-2 (2019)
20-1 (2019)
19-4 (2019)
19-3 (2018)
19-2 (2018)
19-1 (2018)
18-4 (2017)
18-3 (2017)
18-2 (2017)
18-1 (2017)
17-4 (2016)
17-3 (2016)
17-2 (2016)
17-1 (2016)
16-4 (2015)
16-3 (2015)
16-2 (2015)
16-1 (2014)
15-4 (2014)
15-3 (2014)
15-2 (2013)
15-1 (2013)
14-4 (2013)
14-3 (2013)
14-2 (2013)
14-1 (2012)
13-4 (2012)
13-3 (2011)
13-2 (2011)
13-1 (2011)
12-4 (2011)
12-3 (2010)
12-2 (2010)
12-1 (2010)
11-4 (2010)
11-3 (2009)
11-2 (2009)
11-1 (2009)
10-4 (2009)
10-3 (2008)
10-2 (2008)
10-1 (2008)
9-4 (2008)
9-3 (2007)
9-2 (2007)
9-1 (2007)
8-4 (2007)
8-3 (2006)
8-2 (2006)
8-1 (2006)
7-3 (2006)
7-2 (2005)
7-1 (2005)
6-3 (2005)
6-2 (2004)
6-1 (2004)
5-3 (2004)
5-2 (2003)
5-1 (2003)
4-3 (2003)
4-2 (2002)
4-1 (2002)
3-3 (2002)
3-2 (2001)
3-1 (2001)
2-3 (2001)
2-2 (2000)
2-1 (2000)
1-3 (2000)
1-2 (1999)
1-1 (1999)
advertisement